Log in

NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

$608.24
-11.97 (-1.93 %)
(As of 08/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$596.58
Now: $608.24
$624.35
50-Day Range
$605.04
MA: $627.47
$658.21
52-Week Range
$271.37
Now: $608.24
$664.64
Volume624,101 shs
Average Volume670,537 shs
Market Capitalization$66.92 billion
P/E Ratio23.55
Dividend YieldN/A
Beta0.56
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Read More
Regeneron Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:REGN
CUSIP75886F10
Phone914-847-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.86 billion
Cash Flow$23.75 per share
Book Value$100.56 per share

Profitability

Net Income$2.12 billion

Miscellaneous

Employees8,100
Market Cap$66.92 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$608.24
-11.97 (-1.93 %)
(As of 08/10/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, REGN shares have increased by 30.9% and is now trading at $608.24.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 11 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Regeneron Pharmaceuticals
.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Regeneron Pharmaceuticals
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its quarterly earnings data on Wednesday, August, 5th. The biopharmaceutical company reported $7.16 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $1.57. The biopharmaceutical company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.74 billion. Regeneron Pharmaceuticals had a net margin of 37.30% and a return on equity of 26.71%. The company's revenue was up 23.7% on a year-over-year basis. During the same quarter last year, the business posted $6.02 earnings per share.
View Regeneron Pharmaceuticals' earnings history
.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its board has authorized a stock repurchase program on Tuesday, November 5th 2019, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 2.9% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's leadership believes its stock is undervalued.

What price target have analysts set for REGN?

27 brokerages have issued twelve-month price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $325.00 to $800.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $592.78 in the next year. This suggests that the stock has a possible downside of 2.5%.
View analysts' price targets for Regeneron Pharmaceuticals
.

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Headlines about REGN stock have trended positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term.
View the latest news about Regeneron Pharmaceuticals
.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 1,990,000 shares, a decrease of 6.1% from the July 15th total of 2,120,000 shares. Based on an average trading volume of 1,310,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 1.9% of the company's stock are sold short.
View Regeneron Pharmaceuticals' Short Interest
.

Who are some of Regeneron Pharmaceuticals' key competitors?

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Johnson & Johnson (JNJ), Micron Technology (MU), Walt Disney (DIS), Visa (V) and salesforce.com (CRM).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:
  • Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
  • Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
  • Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
  • Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
  • Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.44%), Swiss National Bank (0.44%), First Trust Advisors LP (0.33%), LSV Asset Management (0.29%), Candriam Luxembourg S.C.A. (0.21%) and New York State Common Retirement Fund (0.19%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals
.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., LSV Asset Management, Toronto Dominion Bank, NN Investment Partners Holdings N.V., NN Investment Partners Holdings N.V., Cannell Peter B & Co. Inc., Hancock Whitney Corp, and Nissay Asset Management Corp Japan ADV. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi.
View insider buying and selling activity for Regeneron Pharmaceuticals
.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank, Robeco Institutional Asset Management B.V., First Trust Advisors LP, Sumitomo Mitsui Trust Holdings Inc., Mn Services Vermogensbeheer B.V., PGGM Investments, Principal Financial Group Inc., and Assenagon Asset Management S.A..
View insider buying and selling activity for Regeneron Pharmaceuticals
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $608.24.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $66.92 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.